Stay updated on FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial
Sign up to get notified when there's something new on the FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial page.

Latest updates to the FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded Revision: v3.4.2; removed the funding-status notice and Revision: v3.4.1. These are administrative updates to the site and do not alter study details or eligibility information.SummaryDifference0.4%

- Check21 days agoChange DetectedA new site-wide notice about a lapse in government funding appears on the page, and the revision tag shows v3.4.1 replacing the prior v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check28 days agoChange DetectedAdded a 'Show glossary' option and updated metadata labels (including 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act data'); revision updated to v3.4.0.SummaryDifference0.2%

- Check42 days agoChange DetectedFooter revision updated from v3.3.3 to v3.3.4; no modifications to core study content, eligibility criteria, contact information, locations, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedA new Locations section now lists Santa Monica, California as a study site. The old California Locations block and the HHS Vulnerability Disclosure link were removed, and the revision tag updated to v3.3.3.SummaryDifference0.2%

- Check85 days agoChange DetectedRevision label updated from v3.3.1 to v3.3.2 in the page footer.SummaryDifference0.1%

Stay in the know with updates to FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial page.